Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

421. Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. (Abstract)

Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Thyrotropin-releasing hormones (TRH) added to prenatal corticosteroids has been suggested as a way to further reduce breathing problems and neonatal lung disease in infants born preterm.To assess the effect of giving prenatal TRH in addition to corticosteroids to women at risk of very preterm birth for the prevention of neonatal respiratory disease.We searched (...) trials providing data, was associated with poorer outcomes at childhood follow up. Sensitivity analyses by trial quality, or subgroups with differing times from entry to birth, or different dose regimens of TRH, did not change these findings.Prenatal thyrotropin-releasing hormones, in addition to corticosteroids, given to women at risk of very preterm birth do not improve infant outcomes and can cause maternal side-effects.

2004 Cochrane

422. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Full Text available with Trip Pro

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Anti-leukotrienes agents are currently being studied as alternative first line agents to inhaled corticosteroids in mild to moderate chronic asthma.To compare the safety and efficacy of anti-leukotriene agents with inhaled glucocorticoids (ICS) and to determine the dose-equivalence of anti-leukotrienes to daily dose of ICS.We searched MEDLINE (1966 to Aug 2003 (...) ), EMBASE (1980 to Aug 2003), CINAHL (1982 to Aug 2003), the Cochrane Airways Group trials register, and the Cochrane Central Register of Controlled Trials (August 2003), abstract books, and reference lists of review articles and trials. We contacted colleagues and international headquarters of anti-leukotrienes producers.Randomised controlled trials that compared anti-leukotrienes with inhaled corticosteroids during a minimal 30-day intervention period in asthmatic patients aged 2 years and older.Two

2004 Cochrane

423. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. (Abstract)

Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Duchenne muscular dystrophy is the most common muscular dystrophy of childhood. This incurable disease is characterised by muscle wasting and loss of walking ability leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is one of the major aims of treatment.The aim of this review was to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD.We (...) controlled trials that met the inclusion criteria for our review. Two reviewers independently selected the trials for the review and assessed methodological quality. Data extraction and inputting were double-checked.data from one small study used prolongation of walking as an outcome measure and did not show significant benefit.The meta-analysis of the results from three randomised controlled trials showed that glucocorticoid corticosteroids improved muscle strength and function over six months

2004 Cochrane

424. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Full Text available with Trip Pro

High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Inhaled corticosteroids (ICS) form the basis of maintenance therapy in asthma and their efficacy is well established. However, the optimal starting dose of ICS is not clearly established. Recent reviews demonstrate a relatively flat efficacy curve for ICS and increasing side effects with increasing ICS doses. High doses are frequently prescribed and there are now reports of significant

2004 Cochrane

425. Frequency of application of topical corticosteroids for atopic eczema (TA81)

Frequency of application of topical corticosteroids for atopic eczema (TA81) Overview | Frequency of application of topical corticosteroids for atopic eczema | Guidance | NICE Frequency of application of topical corticosteroids for atopic eczema Technology appraisal guidance [TA81] Published date: 25 August 2004 Share Guidance on using topical corticosteroids for people with atopic eczema. Guidance development process Is this guidance up to date? . We found nothing new that affects

2004 National Institute for Health and Clinical Excellence - Technology Appraisals

426. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation

of the findings is limited. Further research is required on the clinical and cost-effectiveness of once-daily versus more frequent use of same potency corticosteroids, specifically on mild potency products for mild to moderate atopic eczema. Outcomes should include quality of life and compliance. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Adrenal Cortex Hormones; Costs and Cost Analysis; Dermatitis, Atopic Language Published English Country of organisation England Address (...) Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review

2004 Health Technology Assessment (HTA) Database.

427. Frequency of application of topical corticosteroids for atopic eczema

indexing assigned by CRD MeSH Adrenal Cortex Hormones; Dermatitis, Atopic Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800; Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk AccessionNumber 32004000794 Date bibliographic record published 08/10/2004 Date abstract record published 08/10/2004 Health Technology Assessment (HTA) database Copyright © 2019 National Institute for Clinical Excellence (...) Frequency of application of topical corticosteroids for atopic eczema Frequency of application of topical corticosteroids for atopic eczema Frequency of application of topical corticosteroids for atopic eczema National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Frequency

2004 Health Technology Assessment (HTA) Database.

428. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. (Abstract)

Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Asthma self-management plans that include doubling the dose of inhaled corticosteroid when the condition deteriorates improve asthma control. Whether doubling the dose of corticosteroid in isolation is effective is unknown. We undertook a randomised controlled trial to investigate the effects of doubling the dose of inhaled corticosteriods when asthma deteriorates.390 individuals (...) with asthma who were at risk of an exacerbation monitored their morning peak flow and asthma symptoms for up to 12 months. When peak flow or symptoms started to deteriorate, participants added an active or placebo corticosteroid inhaler to their usual corticosteroid for 14 days to produce a doubling or no change in dose. The primary outcome was the number of individuals starting oral prednisolone in each group.During 12 months, 207 (53%) started their study inhaler and 46 (12%) started prednisolone--22

2004 Lancet Controlled trial quality: predicted high

429. Corticosteroid injections for osteoarthritis of the knee: meta-analysis

Corticosteroid injections for osteoarthritis of the knee: meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

430. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity

with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propinate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-80. Indexing Status Subject indexing assigned by NLM MeSH Administration, Inhalation; Adrenal Cortex Hormones /administration & Cost-Benefit Analysis; Drug Costs; Forced Expiratory (...) Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity Sin D D, Golmohammadi K, Jacobs P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

2004 NHS Economic Evaluation Database.

431. Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma

Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma Marchetti M, Cavallo M C, Annoni E, Gerzeli S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four inhaled corticosteroids (ICS) for the treatment of moderate-to-severe asthma were studied. The ICS were beclomethasone (BDP), beclomethasone-extrafine (BDP-EF), fluticasone (FP) and budesonide (BUD). In patients with moderate asthma, the ICS were compared at daily doses of 1,000 microg BDP, 400 microg BDP-EF, 400 microg FP and 800 microg BUD. In patients with severe asthma

2004 NHS Economic Evaluation Database.

432. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2004 PedsCCM Evidence-Based Journal Club

433. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Full Text available with Trip Pro

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Severe acute respiratory syndrome (SARS) is a new clinical entity for which no effective therapeutic strategy has been developed.To provide preliminary results on the potential therapeutic benefit and tolerability of interferon alfacon-1 plus corticosteroids for SARS.Open-label study of 22 patients diagnosed as having probable SARS at North York General Hospital, Toronto, Ontario, between April (...) 11 and May 30, 2003.Thirteen patients were treated with corticosteroids alone and 9 patients were treated with corticosteroids plus subcutaneous interferon alfacon-1.Clinical parameters, including oxygen saturation and requirement, laboratory measures, and serial chest radiography results.Resolution of fever and lymphopenia were similar between the 2 treatment groups. Of the 13 patients treated with corticosteroids alone, 5 (38.5%) were transferred to the intensive care unit, 3 (23.1%) required

2003 JAMA

434. Colchicine as an oral corticosteroid sparing agent for asthma. (Abstract)

Colchicine as an oral corticosteroid sparing agent for asthma. Oral corticosteroids are used as a treatment for asthma, but they are often associated with serious side effects. Colchicine is an anti-inflammatory, immuno modulating agent, which could potentially have a beneficial effect in the treatment of asthma as well as act as a steroid-sparing agent.To determine the effectiveness of colchicine as an oral corticosteroid sparing agent for in the treatment of chronic asthma.We searched

2003 Cochrane

435. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. (Abstract)

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Long-acting beta-agonists and inhaled corticosteroids have been recommended in guidelines for the treatment of chronic obstructive pulmonary disease. However, they have only been available until recently via separate administration. They have been developed in order to facilitate adherence to medication regimens, and to improve efficacy.To assess the efficacy of combined inhaled (...) corticosteroid and long-acting beta-agonist preparations in the treatment of adults with chronic obstructive pulmonary disease.We searched the Cochrane Airways Group chronic obstructive pulmonary disease (COPD) trials register (March 2003), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2003), LILACS (all years to March 2003) and reference lists of articles. We also contacted manufacturers and researchers in the field.Studies were included if they were randomised

2003 Cochrane

436. Corticosteroids for idiopathic pulmonary fibrosis. (Abstract)

Corticosteroids for idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF), also called cryptogenic fibrosing alveolitis (CFA), is a lethal form of diffuse lung disorder of unknown origin; the mean survival being two to four years. Currently recommended and most prescribed therapy for IPF is based on the use of systemic corticosteroids, even if no formal demonstration of efficacy of this treatment of IPF is available. Furthermore, new insights from pathological studies have produced (...) a new hypothesis, based upon the central role played by aberrant wound healing following repeated lung injury, weakening the rationale basis of the use of corticosteroids in IPF, previously considered simply a chronic inflammatory disease.The objective of the review was to determine the efficacy of corticosteroids in the treatment of adults with IPF.We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2002), MEDLINE (January 1966 to May 2002) and EMBASE

2003 Cochrane

437. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. (Abstract)

Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Infants born preterm are at high risk of neonatal lung disease and its sequelae. A single course of prenatal corticosteroids has not been shown to be of benefit in babies who are born more than seven days after treatment. It is not known whether there is benefit in repeating the dose of prenatal corticosteroids to women who remain at risk of preterm birth more than seven days (...) after an initial course.To assess the effectiveness and safety of a repeat dose(s) of prenatal corticosteroids, given to women who remain at risk of preterm birth seven or more days after an initial course of prenatal corticosteroids.We searched the Cochrane Pregnancy and Childbirth Group trials register (January 2003), the Cochrane Controlled Trials Register (The Cochrane Library, Issue 1, 2003), MEDLINE (1965 to January 2003), EMBASE (1988 to January 2003), Current Contents (1997 to January 2003

2003 Cochrane

438. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. Full Text available with Trip Pro

Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. A number of therapies have been proposed for the long-term management of corticosteroid-responsive, rapidly progressive, bilateral sensorineural hearing loss (autoimmune inner ear disease [AIED]). Methotrexate has emerged as the benchmark agent but has not been rigorously evaluated for hearing improvement in patients with AIED.To assess the efficacy of long-term methotrexate

2003 JAMA Controlled trial quality: predicted high

439. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. Full Text available with Trip Pro

Stepping down inhaled corticosteroids in asthma: randomised controlled trial. To determine whether the dose of inhaled corticosteroids can be stepped down in patients with chronic stable asthma while maintaining control.One year, randomised controlled, double blind, parallel group trial.General practices throughout western and central Scotland.259 adult patients with asthma receiving regular treatment with inhaled corticosteroids at high dose (mean dose 1430 microg beclomethasone dipropionate (...) ).Participants were allocated to receive either no alteration to their dose of inhaled corticosteroid (control) or a 50% reduction in their dose if they met criteria for stable asthma (stepdown).Comparison of asthma exacerbation rates, asthma related visits to general practice and hospital, health status measures, and corticosteroid dosage between the two groups.The proportions of subjects with asthma exacerbations were not significantly different (stepdown 31%, control 26%, P=0.354). Similarly, the numbers

2003 BMJ Controlled trial quality: predicted high

440. Cost effectiveness of low dose corticosteroids versus non steroidal anti inflammatory drugs and COX 2 specific inhibitors in the long term treatment of rheumatoid arthritis

Cost effectiveness of low dose corticosteroids versus non steroidal anti inflammatory drugs and COX 2 specific inhibitors in the long term treatment of rheumatoid arthritis Cost effectiveness of low dose corticosteroids versus non steroidal anti inflammatory drugs and COX 2 specific inhibitors in the long term treatment of rheumatoid arthritis Cost effectiveness of low dose corticosteroids versus non steroidal anti inflammatory drugs and COX 2 specific inhibitors in the long term treatment (...) of rheumatoid arthritis Bae S C, Corzillius M, Kuntz K M, Liang M H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of low dose (less than 10 mg/day prednisone) corticosteroids for the treatment of rheumatoid arthritis (RA

2003 NHS Economic Evaluation Database.